scholarly journals Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes

2020 ◽  
Vol 22 (7) ◽  
pp. 1094-1101 ◽  
Author(s):  
Lars Johansson ◽  
Paul D. Hockings ◽  
Eva Johnsson ◽  
Nalina Dronamraju ◽  
Jill Maaske ◽  
...  
Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1175-P
Author(s):  
JOHN P. WILDING ◽  
PAUL HOCKINGS ◽  
EVA K. JOHNSSON ◽  
JILL MAASKE ◽  
RICARDO GARCIA-SANCHEZ ◽  
...  

2014 ◽  
Vol 113 (1) ◽  
pp. 90-97 ◽  
Author(s):  
Weena J.Y. Chen ◽  
Ibrahim Danad ◽  
Pieter G. Raijmakers ◽  
Rick Halbmeijer ◽  
Hendrik J. Harms ◽  
...  

2021 ◽  
Author(s):  
Susan Martin ◽  
Madeleine Cule ◽  
Nicolas Basty ◽  
Jessica Tyrrell ◽  
Robin N. Beaumont ◽  
...  

To understand the causal role of adiposity and ectopic fat in type 2 diabetes and cardiometabolic diseases, we aimed to identify two clusters of adiposity genetic variants, one with ‘adverse’ metabolic effects (UFA) and the other with, paradoxically, ‘favourable’ metabolic effects (FA). We performed a multivariate genome-wide association study using body fat percentage and metabolic biomarkers from UK Biobank and identified 38 UFA and 36 FA variants. Adiposity-increasing alleles were associated with an adverse metabolic profile, higher risk of disease, higher CRP, higher fat in subcutaneous and visceral adipose tissue, liver and pancreas for UFA; and a favourable metabolic profile, lower risk of disease, higher CRP, higher subcutaneous adipose tissue but lower liver fat for FA. We detected no sexual dimorphism. The Mendelian randomization studies provided evidence for risk-increasing effect of UFA and protective effect of FA on type 2 diabetes, heart disease, hypertension, stroke, non-alcoholic fatty liver disease and polycystic ovary syndrome. FA is distinct from UFA by its association with lower liver fat, and protection from cardiometabolic diseases; it was not associated with visceral or pancreatic fat. Understanding the difference in FA and UFA may lead to new insights in preventing, predicting and treating of cardiometabolic diseases.


2008 ◽  
Vol 135 (1) ◽  
pp. 122-130 ◽  
Author(s):  
Anna Kotronen ◽  
Leena Juurinen ◽  
Mirja Tiikkainen ◽  
Satu Vehkavaara ◽  
Hannele Yki–Järvinen

2010 ◽  
Vol 41 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Lutgarda Bozzetto ◽  
Anna Prinster ◽  
Marcello Mancini ◽  
Rosalba Giacco ◽  
Claudia De Natale ◽  
...  

2013 ◽  
pp. n/a-n/a
Author(s):  
Henry J. Jansen ◽  
Gerald M. Vervoort ◽  
Marinette van der Graaf ◽  
Rinke Stienstra ◽  
Cees J. Tack

Sign in / Sign up

Export Citation Format

Share Document